Chrysea Labs (Portugal)

Chrysea Labs is a Portuguese life-sciences company based in Cantanhede that describes itself as operating at the crossroads of synthetic biology, clinical research, bioengineering and data analytics. Its stated purpose is to develop precision nutrients and interventions that support healthy ageing across the lifespan. The company positions itself as an early-commercial-stage business focused on precision nutrition — personalised dietary and supplementation recommendations built on individual characteristics such as genetics, lifestyle, environment and health status — rather than the generalised guidelines typical of conventional nutrition advice. Chrysea's approach is explicitly science-led. The company says its interventions are grounded in clinical research and are designed to support, and where possible manage or delay, the onset of chronic health conditions associated with the natural ageing process. Its data-analytics platform is described as combining several data sources: metabolomics (metabolic responses to foods and supplements), health status (medical history and chronic-disease risk), environmental factors (food access, socioeconomic status and cultural influences), behavioural data (lifestyle habits and preferences) and microbiome analysis (gut bacteria and their implications for digestion and health). The company frames its market opportunity around a shift from a conventional "sick-care" model toward preventive health and wellness, driven by increasingly informed and proactive consumers. It acknowledges that the consumer products market for preventive health and wellness is crowded and poorly regulated but very large, and states that it aims to differentiate itself by creating ingredients, products and proprietary brands that are safe, scientifically validated, functionally superior and trustworthy. Trusted dietary supplements and nutrition interventions are central to this strategy. Chrysea is led by CEO Pedro de Noronha Pissarra, PhD, a life-sciences entrepreneur with a long track record in biotechnology and healthcare. The company's team is described as combining expertise across biology, engineering and data analytics. Its product page currently indicates that products are "coming soon", consistent with its early-commercial stage. The company is headquartered in Cantanhede, Portugal, and presents itself as operating in the healthy-lifespan sector with an international outlook.

Chrysea Labs is a Portuguese life-sciences company headquartered in Cantanhede, Portugal. Public information about the company is limited and largely drawn from its own website, which presents it as an early-commercial-stage enterprise rather than a mature commercial operation. The company describes itself as operating at the innovative crossroads of synthetic biology, clinical research, bioengineering and data analytics, with the goal of developing precision nutrients and interventions for healthy ageing across the lifespan. From its inception, Chrysea has framed its mission around precision nutrition: personalised dietary and supplementation recommendations based on individual characteristics such as genetics, lifestyle, environment and health status. This contrasts with traditional, generalised nutrition guidelines. The company states that its approach is underpinned by rigorous clinical research and is designed to support and, when possible, manage or delay the onset of chronic health conditions associated with the natural ageing process. A central element of Chrysea's strategy is its data-analytics capability, which it describes as combining multiple data sources: metabolomics (analysing metabolic responses to foods and supplements), health status (medical history and chronic-disease risks), environmental factors (food access, socioeconomic status and cultural influences), behavioural data (lifestyle habits and preferences) and microbiome analysis (examining gut bacteria for insights on digestion and health). The company says it aims to improve health outcomes and manage the onset of chronic conditions throughout a consumer's lifetime. Chrysea positions itself in the healthy-lifespan sector, where it says it is leading innovation by creating ingredients, products and proprietary brands that are safe, scientifically validated, functionally superior and trustworthy. It acknowledges that the consumer products market for preventive health and wellness is crowded and poorly regulated, yet massive, and sees trusted dietary supplements and nutrition interventions as an important part of that market. The company links its opportunity to the rise of informed and proactive consumers and a transition from a conventional sick-care model toward preventive health, a shift it says is facilitated by the affordability of diverse products and broadens market access. The company is led by CEO Pedro de Noronha Pissarra, PhD, a seasoned life-sciences entrepreneur with more than 29 years in biotechnology and healthcare. According to the company's website, Pissarra founded the Biotecnol Group in 1996 and sold it in 2018; he also founded RDN, a biopharmaceutical CDMO sold to the Iberfar Group, and Biotecnol Limited, an immuno-oncology company sold to Chiome, Inc. He has served on the boards of Vida Rhein SA (hepatitis vaccines, sold to Dynavax, Inc.) and 4Tune Engineering (data analytics and risk analysis, sold to Valgenesis, Inc.). His background spans biosimilars, immune-checkpoint modulators, financing, licensing, M&A and cross-border transactions. Chrysea's team is described as combining diverse talents across biology, engineering and data analytics, working toward the mission of empowering individuals with science-backed nutritional interventions for a healthier, longer life. As of the company's current product page, products are listed as "coming soon", indicating that Chrysea remains at an early-commercial stage. The company is headquartered in Cantanhede, Portugal, and presents itself with an international outlook in the healthy-lifespan and precision-nutrition space.

• Chrysea Labs is headquartered in Cantanhede, Portugal, and presents itself as an early-commercial-stage company in precision nutrition.

• CEO Pedro de Noronha Pissarra founded the Biotecnol Group in 1996 and sold it in 2018, according to the company's website.

• Chrysea's product page lists products as 'coming soon', indicating the company has not yet launched commercial products.

Science-backed precision nutrition and trusted supplementation for preventive health and healthy ageing, differentiating in a crowded and poorly regulated consumer wellness market.

• Precision nutrition interventions

  Personalised dietary and supplementation recommendations based on genetics, lifestyle, environment and health status.

• Dietary supplements

  Trusted dietary supplements and nutrition interventions positioned as part of preventive health and wellness.

• Nutritional ingredients

  Ingredients, products and proprietary brands that are safe, scientifically validated and functionally superior.

1. 1Chrysea Labschrysealabs.com
2. 2Products - Chrysea Labschrysealabs.com
3. 3Our Vision - Chrysea Labschrysealabs.com
4. 4Our People - Chrysea Labschrysealabs.com
5. 5Chrysea Labs (Portugal) - Wikidatawikidata.org